February 12, 2019 Acad, Gov/Utilities Product Launch

FLIR Launches Industry-First High-Definition Handheld Cooled Optical Gas Imaging Camera for Oil and Gas Inspection Professionals

WILSONVILLE, Ore., February 12, 2019 – FLIR Systems, Inc. (NASDAQ: FLIR) today announced the industry’s first high-definition (HD), handheld optical gas imaging (OGI) camera, the FLIR GF620. Designed for oil and gas industry professionals, the GF620 camera sets a new standard for detecting and visualizing invisible leaks of hydrocarbons, such as methane, and common volatile organic... Read more

February 5, 2019 Acad, Gov/Utilities

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

Basel, 05 February 2019 Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Roche’s application is being reviewed under the US FDA’s Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation... Read more

February 4, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

GE Healthcare and Aga Khan University Hospital Pakistan announce strategic partnership

Dubai, UAE; January 29, 2019: On the sidelines of Arab Health 2019, the region’s leading healthcare exhibition, GE Healthcare and The Aga Khan University Hospital (AKUH) in Karachi, Pakistan, today announced a strategic partnership to give Pakistan’s leading private quaternary care hospital access to a new range of advanced medical imaging and diagnostic equipment. GE... Read more

January 24, 2019 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Shimadzu announces a New Research Facility to drive innovation further as part of the Shimadzu Technology Research Laboratory expansion.

Shimadzu Corporation has announced plans to build the SHIMADZU Future Collaboratory at the Technology Research Laboratory in Keihanna Science City, Kyoto Prefecture, Japan to expand the program of innovation at Shimadzu Corporation. The new laboratory will further drive research and development by focusing on several core themes including artificial intelligence (AI), innovative biotechnology, brain-science and... Read more

January 17, 2019 Acad, Gov/Utilities

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

Basel, 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for... Read more

January 15, 2019 Acad, Gov/Utilities M&A, Partnerships Materials Analysis

MTS Equips University To Test New Materials For Construction And Transportation Industries

EDEN PRAIRIE, Minn., Jan. 15, 2019 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems, motion simulators and sensors, today announced completion of two unique test systems for the Extreme Performance Testing Center at Seoul National University. These test systems—a High-Rate Impact and a High-Force Fatigue system—deliver the velocities... Read more

January 14, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN’s QuantiFERON®-TB Gold Plus gains approval in Canada

Germantown, Maryland and Hilden, Germany, January 14th, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic test to detect latent tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining a new flexible... Read more

January 4, 2019 Acad, Gov/Utilities M&A, Partnerships

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

Chicago and Nashville, USA – January 6, 2019 – GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before... Read more

December 17, 2018 Acad, Gov/Utilities Licensing, IP, and Legal

PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)

Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more

December 10, 2018 Acad, Gov/Utilities Bio/Pharma/CRO Lab Top-10 Life Science Tools M&A, Partnerships

Merck KGaA, Darmstadt, Germany Announces a CRISPR/Cas9 Strategic Alliance to Develop Rodent Models with genOway

10 DEC 2018 | DARMSTADT, GERMANY genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, announced that its life... Read more